XDR-TB in the U.S.

Cases of extensively drug-resistant TB have been reported in this country every year since 1993.

Recent attention has focused on outbreaks of extensively drug-resistant TB (XDR-TB) — i.e., infection with Mycobacterium tuberculosis strains resistant to isoniazid, a rifamycin, a fluoroquinolone, and a second-line injectable agent (JW Infect Dis Aug 6 2008). Treatment options are limited, and the mortality rate is high. CDC investigators analyzed national surveillance data for 1993 through 2007 to define the scope of XDR-TB in the U.S.

During this 15-year period, 212,896 culture-confirmed TB cases were reported in the U.S. Drug-susceptibility results for isoniazid and rifamycin were available for 201,399 of them. A total of 183,536 cases were caused by drug-susceptible (DS) strains; 3379 cases were caused by strains resistant to at least i…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

XDR-TB in the U.S.

Topics

Reviewing Author